Who do you expect will be manufacturing, the Keebler elves? You people are ignorant and myopic.
Well said. This is what happens when retail margin jump on a story with delusions of quick profits.
Absolutely fine to use them as negotiating leverage.
I initially concluded that LLY would be the most likely, but have recently switched camps to Sanofi.
The search for a partner for El Quevar goes back well over a year. Not surprising that this hasn't come to fruition given the PM market, but this can (and I believe will) turn on a dime. I believe El Quevar is being carried on the books at a small premium to land value, as are the other exploration-stage property assets.
"thought it might be Pfizer at first. Just because they failed doesn't mean they shouldn't try again, right?" That is exactly why it won't be Pfizer. You don't risk the franchise on a partner who failed and who still carries the stigma of failure. Further, Al previously called out Pfizer as "not a good option for us". I absolutely agree.
Yes, it's an urban legend. Any shares purchased with margin can be lent by your broker without your consent and regardless of any open orders. Share purchased with cash cannot be lent without explicit consent from the beneficial order. Placinga gtc order is like hanging garlic on your door to prevent vampires.
When you shorted MNKD did you actually believe Exubera and Afrezza were the same drug? That would explain a lot.
It could take some of them out. Completely out. I wonder how this factors into the margin coverage models at the brokers.
What IF Al sells the Afrezza program (holds onto Technosphere and Oncology), then immediately announces a special dividend to shareholders in an amount close to the sale price. Read the following from Investopedia:
When you short a stock, you are borrowing the stock from an investor or broker, then selling those shares on the open market to a second investor. Even though you borrowed and sold the shares to another investor, the transaction between you and the lender is still listed on the books as if the lender is still long on the stock and you are short on the stock (even though that person no longer owns the stock).
Because that original investor who was kind enough to lend you the stock is no longer an actual shareholder with the company, the short seller is required to make up for any benefits the investor would have received had he or she actually still owned the stock.
In other words, if a company pays a dividend to shareholders, the second investor who bought the shares from the short seller would get the dividend check from the company. But because the original investor is no longer a shareholder of record (because the second investor owns those shares now), then the short seller must pay the dividend out of his or her own pocket.
And downgrades to hold from buy based on valuation. That was probably based on the short move above $1.40 yesterday. In any case, they are the only analyst currently covering the stock.
It interesting that the 12 month pps target does not include a write-up in assets that will occur when Valardena re-opens, which could be $4/5 per share. Maybe they are waiting for the mine to actually re-open before adjusting their valuation.
Cynk Technology Corp., a development stage company, focuses on operating a social network. Its social network is based on showing the types of people the user is connected with and associated. The company intends to serve seekers, who want to meet people; mavens, who know a lot of people; and targets, who are people that other people want to meet.
That's actually not true, just an internet myth. If you hold shares in a cash account they cannot be lent without your permission. If you hold shares in a margin account you cannot prevent them from being lent. And, regardless, the big boys just short the ETFs anyway so there is no solution.